Senhwa Biosciences, Inc. (TPEX:6492)

Market Cap	3.36B +1.9%
Revenue (ttm)	1.05M +5.0%
Net Income	-296.60M
EPS	-3.32
Shares Out	89.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,000
Open	37.65
Previous Close	37.55
Day's Range	37.55 - 38.10
52-Week Range	35.10 - 66.50
Beta	0.77
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About Senhwa Biosciences

Senhwa Biosciences, Inc. engages in the development of novel drugs and special active pharmaceutical ingredients. The company offers novel drugs, a small-molecule drugs for treating cancers: G-quadruplex stabilizer Pidnarulex (CX5461) for the treatment of breast cancer and other homologous repair deficiency (HRD) or solid tumors from BRCA1/2 gene mutation; inhibitor of protein kinase CK2 (casein kinase II); and Silmitasertib (CX4945) for the treatment of cholangiocarcinoma, basal cell carcinoma, and medulloblastoma. It also provides technical a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6492

Financial Performance

In 2025, Senhwa Biosciences's revenue was 1.07 million, an increase of 7.00% compared to the previous year's 1.00 million. Losses were -264.77 million, -9.86% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 19, 2026

Data Sources Report a data error